Magic mushroom microdoses could soothe End-of-Life anxiety
NCT ID NCT07063862
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether daily low-dose psilocybin (2-3 mg) can reduce psychological distress in 120 adults with advanced illness who have 2-12 months to live. Participants take the drug four days a week for two weeks, without therapy. The study compares psilocybin to a placebo to see if it safely improves mood and well-being.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin (a psychedelic compound from 'magic mushrooms')
What this could lead to
If it works, this could offer a quick, safe, and accessible way to ease anxiety, depression, and loss of purpose in people with advanced illness.
What could go wrong
This is a small, early-phase trial with only 120 participants. The low dose may not work as well as high-dose psilocybin, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSYCHOLOGICAL DISTRESS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bruyere Health
RECRUITINGOttawa, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
McGill University Health Centre
NOT_YET_RECRUITINGMontreal, Quebec, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Providence Care Hospital
RECRUITINGKingston, Ontario, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
South Lake Regional Health Centre
RECRUITINGNewmarket, Ontario, Canada
Contact Phone: •••-•••-••••
-
St. Joseph's Healthcare
NOT_YET_RECRUITINGLondon, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Ottawa Hospital
NOT_YET_RECRUITINGOttawa, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
William Osler Health System
NOT_YET_RECRUITINGBrampton, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••